CHLA-32Homo sapiens (Human)Cancer cell line

Also known as: CHLA32

AI Summary

No AI-generated summary available for this cell line.

Basic Information

Database IDCVCL_M151
SpeciesHomo sapiens (Human)

Donor Information

Age8
Age CategoryPediatric
SexFemale
Subtype FeaturesEWS-FLI

Disease Information

DiseasePrimitive neuroectodermal tumor
LineageBone
SubtypeEwing Sarcoma
OncoTree CodeES

DepMap Information

Source TypeAcademic lab
Source IDACH-001032_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg342Ter (c.1024C>T)Homozygous-PubMed=29970484
Gene fusionEWSR1EWSR1-FLI1, EWS-FLI1-Type 1 fusionPubMed=15150091

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,11
D13S317
12
D16S539
12
D18S51
18,19
D19S433
13,15
D21S11
28,31
D2S1338
24
D3S1358
16
D5S818
11
D7S820
8,9
D8S1179
13,15
FGA
24
TH01
6,9.3
TPOX
8,10
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.

Harris E., Monks A., Morris J.

Mol. Cancer Ther. 14:2452-2462(2015).

The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation.

Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.

PLoS Genet. 10:E1004475-E1004475(2014).

Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.

Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.

PLoS ONE 8:E80060-E80060(2013).

Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.

Batra S., Reynolds C.P., Maurer B.J.

Cancer Res. 64:5415-5424(2004).